|
Sponsored By: |
||
Miacalcin (calcitonin)Miacalcin (generic name, calcitonin) is used to treat post-menopausal osteoporosis in women who have low bone mass but cannot take estrogen (hormone replacement therapy). The drug is usually recommended to women who been post-menopausal for at least five years. Miacalcin comes in the form of a nasal spray (not an inhaler) that enters the bloodstream quickly to help strengthen bone and prevent bone loss. Side effects of Miacalcin may include:
Percutaneous VertebroplastyPercutaneous vertebroplasty (PV) is a new treatment that involves injecting a special liquid cement into fractured vertebral sections. It is being performed at select centers across the U.S. PV is used to fill holes or fractures in the spinal column left from osteoporosis, a degenerative bone disease. PV helps rebuild the collapsed spine and relieves pain and pressure. In a recent study, 29 of 30 patients experienced significant pain relief immediately after the procedure and 80% of the patients reported lasting pain relief. Before the procedure, patients are given a mild sedative. To perform the minimally invasive operation, a surgeon places a needle through the skin into the area of the spine needing treatment. X-ray fluoroscopy is used to help guide the needle. Once the needle is positioned properly, a special liquid cement (called polymethylmethacrylate) is injected into the spinal fracture. Once injected, the liquid cement takes approximately 20 minutes to harden. When it hardens, it becomes a permanent spinal reinforcement. In many cases, a second needle puncture is needed to fill the other side of the vertebra. Possible side effects of PV include:
Experimental TreatmentsIn addition to the therapies outlined in this article, researchers are currently investigating a variety of other medicines to treat and prevent osteoporosis. These investigational methods include:
Several clinical trials are currently underway to investigate these new treatments. Patients with osteoporosis should ask their physicians about new methods to treat the disease.
Monitoring the Treatment of Osteoporosis with Bone Densitometry
Many physicians use bone densitometry to monitor patients with osteoporosis. While effects of treatments may begin soon after therapy is begun, evidence of a response to hormone replacement therapy or other drug treatments may not be accurately detected using DEXA bone densitometry right away. For this reason, osteoporosis patients usually have bone scans at one to two year intervals to monitor treatment responses. Patients at high risk of rapid bone loss (for example, patients on steroid therapy) may receive bone densitometry more frequently. Natural bone loss (not drug related) almost never occurs so rapidly as to require densitometry tests more frequently than at one to two year intervals. Additional Lifestyle ChangesIn addition to treatment with vitamins and drugs, women who have osteoporosis may need to make lifestyle changes. The National Osteoporosis Foundation recommends the following guidelines to avoid bone fractures:
Additional Resources and References
Updated: April 7, 2008 |
||
Imaginis.com suscribes to the HONcode principles of the Health on the Net Foundation.
Copyright 1997-2009 Imaginis Corporation. All rights reserved. Imaginis® is a registered service mark of Imaginis Corporation, a health services company. All other trademarks and copyrights are property of their respective owners. Note: Use of this online service is subject to the disclaimer and the terms and conditions contained herein. Information found within the Imaginis.com website or in other sites linked to from Imaginis.com is provided for educational purposes only and is not intended to be used as a substitute for diagnosis and treatment by a medical doctor. Imaginis does not endorse and has no responsibility for the content of any other sites listed on Imaginis.com, and provides links and references merely as a convenience to its users. Seek immediate medical attention if your condition is urgent. Imaginis - The Breast Cancer Resource